Ascendis Pharma Q3 2024 Earnings Preview
Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The consensus EPS Estimate is -$1.65 (+42.7% Y/Y) and the consensus Revenue Estimate is $76.
Reading International: Q3 Earnings Snapshot
(RDI) on Thursday reported a loss of $6.9 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 31 cents. The movie theater owner posted revenue of $60.1 million in the period.
Pieris Pharmaceuticals: Q3 Earnings Snapshot
Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of $2.19. This story was generated by Automated Insights ( using data from Zacks Investment Research.
SuperCom: Q3 Earnings Snapshot
(SPCB) on
Lifeway: Q3 Earnings Snapshot
Lifeway Foods Inc. (LWAY)
Telesat: Q3 Earnings Snapshot
The Ottawa, Ontario-based company said it had net income of 90 cents per share. Losses, adjusted for non-recurring gains, were 8 cents per share. The satellite communications company posted revenue of $101.
Abeona Therapeutics: Q3 Earnings Snapshot
Abeona Therapeutics shares have climbed 22% since the beginning of the year. The stock has risen 36% in the last 12 months. This story was generated by Automated Insights ( using data from Zacks Investment Research.
Curis: Q3 Earnings Snapshot
Curis Inc. (CRIS) on
Ascendis Pharma Expands Capital to Fuel Growth
Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...
GlobalData on MSN9d
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...
pharmaphorum9d
Novo puts $285m into monthly GLP-1 based on Ascendis tech
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
Ascendis Pharma and Novo Nordisk Join Forces
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
PMLiVE7d
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
FierceBiotech10d
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
MedCity News10d
Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs
The Danish pharmaceutical giant is putting up $285 million to begin a strategic alliance granting the pharmaceutical giant access to Ascendis Pharma technology that could develop its drugs for ...
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
Business Insider26m
BioCryst (BCRX) Receives a Buy from Bank of America Securities
The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, ...
Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate
Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...